SOURCE: Emerging World Pharma Inc.

March 22, 2010 16:28 ET

Emerging World Pharma Inc. First Line of Production Equipment Commences in West African Generic Pharmaceutical Manufacturing Facility

Company Plans to Exercise Profit Sharing Investment Option

MANASSAS, VA--(Marketwire - March 22, 2010) -  Emerging World Pharma Inc. (PINKSHEETS: EWPI) -- After recently returning from a tour of generic drug manufacturing facilities in West Africa, Emerging World Pharma president, Brandon Keks reports that the generic drug manufacturing firm the company has invested in has begun installation on the first line of production equipment in its manufacturing facility in Sunyani, Ghana with a second line of equipment to follow. The company expects the first line of production equipment to be operational in April.

The drugs are to be marketed and sold for private and public sale and use throughout West Africa.

"We expect to have the initial revenues from the first line of production within the second quarter of 2010. Based on what we expect to be a high rate of return the company anticipates exercising its option to significantly increase profit sharing with an additional investment," stated Emerging World Pharma president, Brandon Keks.

Once both manufacturing lines are operational the company expects yearly revenues to exceed in excess of 20 million USD. According to an IMS forecast imports of finished products account for over 60% of the African pharmaceutical industry.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations. The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact Information

  • Contact: Joel Everret
    Emerging World Pharma Inc.
    Investor Relations Division
    703-646-2633
    Email: info@emergingpharma.com